Threshold Pharmaceuticals should be bought ahead of data, says Stifel.
Stifel expects Threshold to report positive data at the end of May on its TH
-302 for the treatment of glioblastoma and multiple myeloma. The firm thinks
this is an ideal time to buy the stock.